Please try another search
For the nine months ended 30 September 2018, Loxo Oncology Inc revenues increased from $0K to $123.5M. Net loss decreased 67% to $42.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest income, net increase from $2M to $8.4M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$4.55 to -$1.39.
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Revenue | 42.47 | 42.6 | 38.43 | 21.3 |
Gross Profit | ||||
Operating Income | -30.32 | -14.7 | -5.75 | -22.11 |
Net Income | -27.06 | -11.73 | -3.56 | -20.63 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Assets | 659.23 | 716.51 | 748.61 | 783.44 |
Total Liabilities | 280.01 | 324.39 | 364.19 | 405.23 |
Total Equity | 379.21 | 392.12 | 384.42 | 378.21 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 0 Months |
Cash From Operating Activities | 13.42 | 74.85 | 109.77 | 107.76 |
Cash From Investing Activities | -29.43 | -76.33 | -148.24 | -374.16 |
Cash From Financing Activities | 10.1 | 7.11 | 0.23 | 378.05 |
Net Change in Cash | -5.91 | 5.63 | -38.24 | 111.65 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review